| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-06 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.15 | 6e-06 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.14 | 1e-05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.21 | 1e-05 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.22 | 3e-05 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.22 | 3e-05 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.15 | 3e-05 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.13 | 4e-05 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.21 | 5e-05 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.14 | 6e-05 |